Home Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer ...
 

Keywords :   


Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer ...

2015-12-09 01:44:52| Biotech - Topix.net

Oncothyreon Inc. , a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced updated data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of HER2-positive metastatic breast cancer. The data will be the subject of two presentations at the San Antonio Breast Cancer Symposium being held December 8-12, 2015 in San Antonio, TX.

Tags: data cancer breast announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11Boeing makes 38% pay rise offer in bid to end strike
01.11The house paints that promise much more than colour
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11How Japan's youngest CEO transformed Hello Kitty
31.10Unicharm to Expand in Africa
More »